Sign In
Buy CELZ
$2.20
-0.0300 (-1.35%)
At Close: Jun 03, 2026
Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 Study Positive Interim Blinded Data Supports Advancement Toward Potential Pivotal Phase 3 Study
Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $3.7 Million Gross Proceeds
08:10am, Thursday, 06'th Mar 2025
PHOENIX, March 06, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a leading biotechnology innovator in regenerative medicine, today announced
PHOENIX, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology" or the "Company") (NASDAQ: CELZ), a pioneering biotechnology firm specializing in r
Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program
09:25am, Tuesday, 11'th Feb 2025
Significant Efficacy and No Serious Adverse Effects Observed with CELZ-201 Significant Efficacy and No Serious Adverse Effects Observed with CELZ-201
Creative Medical Technology Holdings Expands Collaboration with Greenstone Biosciences to Accelerate iPSCelz Pipeline Development
08:25am, Wednesday, 05'th Feb 2025
PHOENIX, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical”), a clinical-stage biotechnology company advancing regenerative medicine so
PHOENIX, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative medicine, today announced promising
PHOENIX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology leader in regenerative medicine, is pleased to announce the successful completion
PHOENIX, July 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology
Creative Medical Technology Holdings Provides Corporate Update
08:30am, Wednesday, 10'th Jul 2024
PHOENIX, July 10, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a rege
PHOENIX, June 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology
Creative Medical Technology Holdings Provides Corporate Update
09:00am, Wednesday, 27'th Mar 2024
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approac
Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101
12:06pm, Thursday, 07'th Mar 2024
Creative Medical's (CELZ) CELZ-101 gets FDA's Orphan Drug designation for preventing allograft rejection in type-I diabetes patients undergoing pancreatic islet cell transplantation. Stock rises.
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The com
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
07:00am, Wednesday, 06'th Mar 2024
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocri
Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial
08:57am, Thursday, 21'st Dec 2023
New York, December 21, 2023 – Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has received FDA clearance to conduct a phase 1/2 clinical trial using the company's innovative StemSpine
